Background:
- Targeted therapy in folate receptor alpha (FOLR1)-positive high grade serous ovarian carcinoma (HG) is now a mainstay for platinum-resistant disease.
- The rate of FOLR1-positivity in low grade serous ovarian carcinoma (LG) is unknown.
- We compared the genomic and transcriptomic landscapes in FOLR1-positive/negative LG in comparison to its HG counterpart.